Overview

AevisBio is a biotech company advancing Targeted Protein Modulator (TPM) technologies, with a focus on Molecular Glue (MG) development, to deliver first-in-class therapies that improve human health and well-being.

We are committed to addressing unmet medical needs for patients suffering from aging-related conditions and diseases through our TPM technology, which overcomes the current limitations of drug development. Our areas of interest include, but are not limited to, drug-resistant cancers, vascular diseases, immune disorders, and neurodegenerative diseases. By advancing highly innovative and differentiated medicines with TPM technology, we aim to deliver not only clinical benefits but also broader human wellfare.